Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's ...

FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

At the four new sites, Lilly expects to create more than 3,000 jobs for engineers, scientists, operations personnel, and lab technicians.

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its ...

DelveInsight's High Potency Active Pharmaceutical Ingredients Market Insights report provides the current and forecast market ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

Stanley Druckenmiller is a retired hedge fund manager of Duquesne Capital, which focuses on macro investment strategy. His fund constantly delivered high returns, and in 2010, when the fund failed to ...